QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 06/09/2024 BST 5-day change 1st Jan Change
43.45 USD -2.36% Intraday chart for QuidelOrtho Corporation +2.84% -41.04%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
QuidelOrtho Shares Rise After Craig-Hallum Upgrade MT
Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40 MT
Transcript : QuidelOrtho Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:00 AM
QuidelOrtho Says FDA Approved Syphilis Assay on Disease-Testing Platform MT
Transcript : QuidelOrtho Corporation, Q2 2024 Earnings Call, Jul 31, 2024
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q2 Revenue $637M, vs. Street Est of $614.9M MT
QuidelOrtho Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
QuidelOrtho Corporation(NasdaqGS:QDEL) added to S&P 600 Health Care CI
QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400 Health Care CI
QuidelOrtho Corporation(NasdaqGS:QDEL) added to S&P 600 CI
QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400 CI
Avantor to Replace Quidel in S&P MidCap 400; Quidel to Replace Hibbett in S&P SmallCap 600 MT
RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating MT
QuidelOrtho Seeks Inorganic Options CI
Transcript : QuidelOrtho Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 01:20 PM
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ CI
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say RE
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Jana Partners Acquires Stake in QuidelOrtho MT
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say RE
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating MT
Tranche Update on QuidelOrtho Corporation's Equity Buyback Plan announced on August 17, 2022. CI
Transcript : QuidelOrtho Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Posts Q1 Revenue $711M, vs. Street Est of $695.1M MT
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q1 EPS $0.44, vs. Street Est of $0.40 MT
Chart QuidelOrtho Corporation
More charts
Logo QuidelOrtho Corporation
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Employees
7,100
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
43.45USD
Average target price
52.80USD
Spread / Average Target
+21.52%
Consensus
  1. Stock Market
  2. Equities
  3. QDEL Stock
  4. News QuidelOrtho Corporation
  5. QuidelOrtho Terminates CEO Douglas Bryant, Postpones Investor Day
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW